Provided by Tiger Trade Technology Pte. Ltd.

BridgeBio Pharma, Inc.

65.75
+0.40000.61%
Pre-market: 66.851.10+1.67%09:24 EDT
Volume:1.78M
Turnover:117.07M
Market Cap:12.87B
PE:-18.42
High:66.42
Open:65.35
Low:65.20
Close:65.35
52wk High:93.42
52wk Low:52.75
Shares:195.81M
Float Shares:167.00M
Volume Ratio:0.68
T/O Rate:1.07%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5686
EPS(LYR):-3.7850
ROE:-1789.67%
ROA:-26.00%
PB:-5.12
PE(LYR):-17.37

Loading ...

BridgeBio Says FDA Accepts Infigratinib NDA for Achondroplasia, Grants Priority Review

Reuters
·
3 hours ago

BridgeBio's Encaleret Shows Symptoms, Bone Turnover Improvements in Phase 3 Trial in ADH1

MT Newswires Live
·
Yesterday

BridgeBio announces real-world evidence, Phase 3 ATTRibute CM sub-analyses

TIPRANKS
·
Yesterday

BridgeBio Pharma presents results from Phase 3 CALIBRATE trial of encaleret

TIPRANKS
·
Yesterday

BridgeBio Says Real-World EHR Study Links Acoramidis to 18% Lower Composite Risk vs Tafamidis in ATTR-CM

Reuters
·
Yesterday

BridgeBio Says FDA Accepts Encaleret NDA for ADH1, Sets May 8, 2027 PDUFA Date

Reuters
·
Oct 11

Encaleret Increased Bone Turnover and Improved Participant-Reported Symptoms in the Phase 3 Calibrate Trial in Adh1

THOMSON REUTERS
·
Oct 11

BridgeBio Pharma is Maintained at Overweight by Barclays

Dow Jones
·
Oct 07

Analysts Conflicted on These Healthcare Names: BridgeBio Pharma (BBIO) and Vaxcyte (PCVX)

TIPRANKS
·
Oct 07

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Oct 07

BridgeBio Pharma (BBIO) Receives a Buy from Barclays

TIPRANKS
·
Oct 07

Will Priority Review Change BridgeBio Pharma Stock Narrative

Simply Wall St.
·
Oct 07

BridgeBio to Present New Real-World Study Comparing Acoramidis vs Pfizer’s Tafamidis in ATTR-CM at HFSA 2026

Reuters
·
Oct 07

BridgeBio Rises on FDA Priority Review for Dwarfism Drug

Reuters
·
Oct 06

BridgeBio Pharma announces FDA acceptance of oral infigratinib NDA

TIPRANKS
·
Oct 06

BridgeBio Pharma - to Submit Maa for Achondroplasia to Ema in Q4 2026

THOMSON REUTERS
·
Oct 06

BridgeBio Pharma - Anticipates U.S. Launch of Oral Infigratinib upon Approval

THOMSON REUTERS
·
Oct 06

BridgeBio Pharma - FDA Sets Pdufa Target Action Date of February 4, 2027 for Oral Infigratinib

THOMSON REUTERS
·
Oct 06

BridgeBio Announces FDA Acceptance and Priority Review of Nda for Oral Infigratinib for Children with Achondroplasia

THOMSON REUTERS
·
Oct 06

What Is Drawing Fresh Attention To BridgeBio Pharma (BBIO)?

Simply Wall St.
·
Oct 06